Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Anti-thymocyte globulin

HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors 2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
GvHD prophylaxis post-alloSCT: PTCy versus ATG 2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD setting 2:03
The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD setting
Leonido Luznik • 21 Oct 2023
Aplastic anemia updates: RACE, the role of anabolic steroids, clonal architecture & more 2:33
Aplastic anemia updates: RACE, the role of anabolic steroids, clonal architecture & more
Austin Kulasekararaj • 5 May 2023
Advances in GvHD prophylaxis & treatment 1:35
Advances in GvHD prophylaxis & treatment
Anna Sureda • 4 May 2023
Evolution & goals of GvHD prophylaxis strategies 2:33
Evolution & goals of GvHD prophylaxis strategies
Rebecca Gonzalez • 16 Feb 2023
ATG-based immunosuppressive therapy in elderly patients with aplastic anemia 1:42
ATG-based immunosuppressive therapy in elderly patients with aplastic anemia
Jayastu Senapati • 11 Dec 2022
The role of haploidentical transplantation in myelofibrosis 1:31
The role of haploidentical transplantation in myelofibrosis
Nico Gagelmann • 28 Oct 2022
Insights into the efficacy of different strategies to prevent acute & chronic GvHD 1:51
Insights into the efficacy of different strategies to prevent acute & chronic GvHD
Christopher Kanakry • 28 Oct 2022
Can adding ATG to PTCy further reduce the risk of GvHD? 1:09
Can adding ATG to PTCy further reduce the risk of GvHD?
Alexandros Spyridonidis • 29 Oct 2022
The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts 2:53
The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts
Miguel-Angel Perales • 28 Oct 2022
Prolymphocytes as a promising GvHD prophylaxis 1:53
Prolymphocytes as a promising GvHD prophylaxis
Miguel-Angel Perales • 28 Oct 2022
Use of belimumab for prophylaxis of chronic GvHD 5:47
Use of belimumab for prophylaxis of chronic GvHD
Iskra Pusic • 24 Apr 2022
Predicting immune reconstitution following alloHSCT 4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
PTCy vs ATG in ALL in haploidentical, unrelated and sibling donor transplantation 3:50
PTCy vs ATG in ALL in haploidentical, unrelated and sibling donor transplantation
Arnon Nagler • 21 Mar 2022
Methotrexate vs MMF with cyclosporine and ATG in MUD transplantation with RIC in patients with AML 1:34
Methotrexate vs MMF with cyclosporine and ATG in MUD transplantation with RIC in patients with AML
Giorgia Battipaglia • 25 Mar 2022
The content of VJHemOnc is intended for healthcare professionals